Comparing Krystal Biotech (NASDAQ:KRYS) and AVROBIO (NASDAQ:AVRO)

Krystal Biotech (NASDAQ:KRYSGet Free Report) and AVROBIO (NASDAQ:AVROGet Free Report) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations and dividends.

Institutional and Insider Ownership

86.3% of Krystal Biotech shares are held by institutional investors. Comparatively, 62.6% of AVROBIO shares are held by institutional investors. 14.1% of Krystal Biotech shares are held by insiders. Comparatively, 9.2% of AVROBIO shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Krystal Biotech and AVROBIO, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Krystal Biotech 0 0 9 0 3.00
AVROBIO 0 2 0 0 2.00

Krystal Biotech presently has a consensus target price of $177.63, suggesting a potential upside of 1.60%. AVROBIO has a consensus target price of $24.00, suggesting a potential upside of 1,614.29%. Given AVROBIO’s higher probable upside, analysts plainly believe AVROBIO is more favorable than Krystal Biotech.

Earnings and Valuation

This table compares Krystal Biotech and AVROBIO’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Krystal Biotech $50.70 million 98.48 $10.93 million $1.87 93.49
AVROBIO N/A N/A $12.16 million $0.69 2.03

AVROBIO has lower revenue, but higher earnings than Krystal Biotech. AVROBIO is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Krystal Biotech has a beta of 0.9, meaning that its share price is 10% less volatile than the S&P 500. Comparatively, AVROBIO has a beta of 1.23, meaning that its share price is 23% more volatile than the S&P 500.

Profitability

This table compares Krystal Biotech and AVROBIO’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Krystal Biotech N/A -5.74% -5.45%
AVROBIO N/A -50.52% -47.13%

Summary

Krystal Biotech beats AVROBIO on 9 of the 12 factors compared between the two stocks.

About Krystal Biotech

(Get Free Report)

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

About AVROBIO

(Get Free Report)

AVROBIO, Inc., a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1 and 3; AVR-RD-01, which is in phase 2 clinical trials for the treatment of Fabry disease; and AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.